Peters GJ - Search Results

1

EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.

Galvani E, Peters GJ, Giovannetti E. Galvani E, et al. Among authors: peters gj. Future Oncol. 2012 Aug;8(8):1015-29. doi: 10.2217/fon.12.89. Future Oncol. 2012. PMID: 22894673 Review.

2

Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.

van Moorsel CJ, Pinedo HM, Veerman G, Guechev A, Smid K, Loves WJ, Vermorken JB, Postmus PE, Peters GJ. van Moorsel CJ, et al. Among authors: peters gj. Biochem Pharmacol. 1999 Feb 15;57(4):407-15. doi: 10.1016/s0006-2952(98)00316-5. Biochem Pharmacol. 1999. PMID: 9933029

3

Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.

Van Triest B, Peters GJ. Van Triest B, et al. Among authors: peters gj. Oncology. 1999 Oct;57(3):179-94. doi: 10.1159/000012030. Oncology. 1999. PMID: 10545786 Review.

4

Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.

Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ. Kroep JR, et al. Among authors: peters gj. J Clin Oncol. 1999 Jul;17(7):2190-7. doi: 10.1200/JCO.1999.17.7.2190. J Clin Oncol. 1999. PMID: 10561275 Clinical Trial.

5

Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.

Giaccone G, González-Larriba JL, van Oosterom AT, Alfonso R, Smit EF, Martens M, Peters GJ, van der Vijgh WJ, Smith R, Averbuch S, Fandi A. Giaccone G, et al. Among authors: peters gj. Ann Oncol. 2004 May;15(5):831-8. doi: 10.1093/annonc/mdh188. Ann Oncol. 2004. PMID: 15111354 Free article. Clinical Trial.

6

Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.

Kroep JR, Smit EF, Giaccone G, Van der Born K, Beijnen JH, Van Groeningen CJ, Van der Vijgh WJ, Postmus PE, Pinedo HM, Peters GJ. Kroep JR, et al. Among authors: peters gj. Cancer Chemother Pharmacol. 2006 Oct;58(4):509-16. doi: 10.1007/s00280-006-0191-z. Epub 2006 Mar 7. Cancer Chemother Pharmacol. 2006. PMID: 16523337 Clinical Trial.

7

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.

Giovannetti E, Backus HH, Wouters D, Ferreira CG, van Houten VM, Brakenhoff RH, Poupon MF, Azzarello A, Pinedo HM, Peters GJ. Giovannetti E, et al. Among authors: peters gj. Br J Cancer. 2007 Mar 12;96(5):769-75. doi: 10.1038/sj.bjc.6603639. Br J Cancer. 2007. PMID: 17339891 Free PMC article.

8

Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia.

Giovannetti E, Ugrasena DG, Supriyadi E, Vroling L, Azzarello A, de Lange D, Peters GJ, Veerman AJ, Cloos J. Giovannetti E, et al. Among authors: peters gj. Leuk Res. 2008 Jan;32(1):19-24. doi: 10.1016/j.leukres.2007.02.011. Epub 2007 Mar 28. Leuk Res. 2008. PMID: 17395259

9

A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.

Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, van de Velde H, Giaccone G. Voortman J, et al. Among authors: peters gj. Clin Cancer Res. 2007 Jun 15;13(12):3642-51. doi: 10.1158/1078-0432.CCR-07-0061. Clin Cancer Res. 2007. PMID: 17575229 Clinical Trial.

10

Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.

Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ. Giovannetti E, et al. Among authors: peters gj. Mol Pharmacol. 2008 Apr;73(4):1290-300. doi: 10.1124/mol.107.042382. Epub 2008 Jan 10. Mol Pharmacol. 2008. PMID: 18187583

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

761 results

Search Page